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Summary Nine human small-cell lung cancer cell lines were treated with transforming growth factor ,
(TGF-,B,). Seven of the cell lines expressed receptors for transforming growth factor P (TGF-p-r) in different
combinations between the three human subtypes I, II and III, and two were receptor negative. Growth
suppression was induced by TGF-P, exclusively in the five cell lines expressing the type II receptor. For the
first time growth suppression by TGF-P, of a cell line expressing the type II receptor without coexpression of
the type I receptor is reported. No effect on growth was observed in two cell lines expressing only type III
receptor and in TGF-p-r negative cell lines. In two cell lines expressing all three receptor types, growth
suppression was accompanied by morphological changes. To evaluate the possible involvement of the
retinoblastoma protein (pRb) in mediating the growth-suppressive effect of TGF-p1, the expression of
functional pRb, as characterised by nuclear localisation, was examined by immunocytochemistry. Nuclear
association of pRb was only seen in two of the five TGF-p,-responsive cell lines. These results indicate that in
SCLC pRb is not required for mediation of TGF-PI-induced growth suppression.
The transforming growth factor betas (TGF-P) constitute a
family of polypeptides which have been shown to be multi-
functional regulators of basic cellular functions such as pro-
liferation, differentiation, cell adhesion and interactions with
extracellular matrix (Massague, 1990; Roberts & Sporn,
1990; Moses, 1992).
Five different isoforms of TGF-P have been described, of
which a wide range of human cells express TGF-p1, TGF-P2,
and TGF-P3 (Derynck et al., 1985, 1988; de Martin et al.,
1987; ten Dijke et al., 1988). TGF-P binds to cell membrane-
bound receptors. Three types (TGF-,-rI, -II and -III) are
expressed by a variety of human cells, both normal and
malignant (for review see Massague et al., 1992). TGF-P-rI
and -II are glycoproteins and their recent cloning revealed an
intracellular serine/threonine kinase domain (Lin et al., 1992;
Ebner et al., 1993), which is believed to play a role in the
initial signal transduction. It has been proposed that
TGF-P-rI and -II signal through formation of a hetero-
dimeric complex (Wrana et al., 1992). TGF-P-rIII, which is a
proteoglycan (betaglycan), has also been cloned (Lopez-
Casillas et al., 1991; Wang et al., 1991) and apparently has
no direct role in signal transduction, but may act as a
capacitor for the signalling receptors. TGF-P1 exerts a
growth-suppressive effect on a wide range of normal (Mas-
sague, 1990) and malignant human cells, including ovarian
carcinoma (Berchuck et al., 1992), mammary carcinoma
(Knabbe et al., 1987; Arteaga et al., 1988), endometrial car-
cinoma (Boyd & Kaufman, 1990), colon carcinoma (Wu et
al., 1992), prostate carcinoma (Wilding et al., 1989) and
gastric carcinoma (Yanagihara & Tsumuraya, 1992). Only
one small-cell lung cancer (SCLC) cell line has previously
been reported to be growth inhibited by TGF-P (Lagadec et
al., 1991).
The intracellular signalling pathway of TGF-P is still ob-
scure. The protein product of the retinoblastoma gene (pRb)
has been proposed to be involved in the pathway mediating
TGF-P1 growth inhibition in vitro in mink lung cells (Laiho
et al., 1990a) and in human keratinocytes (Pietenpol et al.,
1990). In contrast, it has been shown that in a mammary
carcinoma cell line pRb is not an obligatory component of
this pathway (Ong et al., 1991). Retinoblastoma protein has
properties of a cell cycle regulatory factor in that its phos-
phorylation state varies through the cell cycle, with a highly
phosphorylated form predominating in S and G2/M, and an
underphosphorylated form predominating in GI. Aberrant,
non-functional, protein products of mutated Rb genes have
been characterised and shown to have lost the ability to
become hyperphosphorylated and to associate with nuclear
structures (Szekely et al., 1991; Templeton et al., 1991).
Recently, the expressions of TGF-P-r types I, II and III
were examined by chemical cross-linking to TGF-P3 in a
panel of 21 human small-cell lung cancer cell lines (SCLCs)
in our laboratory (Damstrup et al., 1993). Different combina-
tions of the three receptor types were expressed in seven cell
lines. Using the Northern blotting technique the expression
of TGF-pl, TGF-P2 and TGF-P3 mRNAs was examined and
coexpression of TGF-p-r and TGF-P mRNA was found in
six cell lines. Another six cell lines were found only to express
TGF-P mRNA.
The expression of Rb mRNA and pRb in the panel of
SCLC cell lines has been reported previously (Rygaard et al.,
1990). Using Western blotting, it was shown that in five of
the 17 cell lines phosphorylated pRb was expressed,
indicating expression of a functional retinoblastoma protein.
In this study the functionality of the TGF,B receptors in
SCLC and the possible involvement of pRb in mediating the
effect of TGF-P, were investigated. We characterised the
effect on the growth of the seven TGF-,-r-positive and of
two TGF-p-r negative cell lines of continuous treatment with
exogenous TGF-pl, and evaluated the subcellular localisation
of pRb by immunocytochemistry. The results showed that
TGF-P, induced growth suppression in five SCLC cell lines,
and that the growth suppression was found exclusively in the
cell lines expressing TGF-p-r type II. We report for the first
time TGF-,I-induced growth suppression of a cell line ex-
pressing the type II receptor without coexpression of the type
I receptor. Retinoblastoma protein was not an obligatory
component of the pathway mediating the effect of TGF-p1,
since only two of the growth-suppressed cell lines also exp-
ressed functional pRb, as characterised by nuclear localisa-
tion and phosphorylation.
In the two cell lines expressing all three types of TGF-P-r,
growth suppression by TGF-P1 was accompanied by mor-
phological changes at the light microscopical level.
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Materials and methods
Cell lines
SCLC cell lines were cultured in 150 cm2 flasks at 37°C, in an
atmosphere of 5% carbon dioxide and 80% humidity in
medium containing 10% inactivated (56°C, 30 min) fetal calf
serum (FCS) (Flow Laboratories, Irvine, UK) without anti-
biotics. A total of nine SCLC cell lines established from six
patients and characterised as SCLC cell lines in three
different laboratories were examined. Three cell lines estab-
lished at Dartmouth Medical School (Hanover, NH, USA)
(DMS 53, DMS 114, DMS 273) (Pettengill et al., 1980;
Sorenson et al., 1984) were cultured in Waymouth medium
(Gibco, Paisley, UK). Four cell lines established at Gron-
ingen Lung Cancer Center (Groningen, The Netherlands)
(GLC 3, GLC 14, GLC 16, GLC 19) (De Leij et al., 1985;
Berendsen et al., 1988) were cultured in RPMI-1640 (Gibco),
and two cell lines established in our laboratory (CPH 54A,
CPH 54B) (Engelholm et al., 1986) were grown in EMEM
(Eagle's minimum essential medium) (Gibco). AKR-2B, a
mouse fibroblast cell line that has previously been reported to
be TGF-p-r positive, (Tucker et al., 1984), was cultured in
EMEM supplemented with 10% FCS, and used in the dis-
placement assay described below. AKR-2B was kindly pro-
vided by Professor H.L. Moses (Vanderbilt University, TN,
USA). The cells were passaged twice a week. Cells growing
as monolayer cultures (CPH 54A, CPH 54B, DMS 53, DMS
114, DMS 273) were passaged with trypsin. Cells growing as
floating aggregates (GLC 3, GLC 14, GLC 16, GLC 19) were
allowed to sediment before replacing the medium. All cell
lines were routinely checked for, and found to be free of,
mycoplasma infection.
Growthfactor
Porcine TGF-P, was purchased from British Biotechnology
(Oxford, UK) and/or was a gift from Bristol-Myers Squibb
(Pharmaceutical Research Institute, Seattle, WA, USA). One
microgram of dried TGF-P, was reconstituted in 0.5 ml of
4 mM hydrochloric acid containing 2 mgml-l BSA, and
stored at + 4°C. Fresh TGF-1, stock solution was tested for
the ability to displace '25I-labelled TGF-3, in AKR-2B cells
using a radioreceptor assay as described elsewhere (Damstrup
et al., 1993). For growth assays, solutions of TGF-P, in
culture medium containing 10% inactivated (56°C, 30 min)
FCS without antibiotics were made immediately before each
experiment.
Growth assay
Exponentially growing cells were harvested as described
above, resuspended in PBS and centrifuged at 275g for
5 min. A single-cell suspension was obtained by mechanical
disaggregation. Cells were counted in a haemocytometer and
viability was evaluated by trypan blue exclusion. Viable cells
were seeded in 35 mm six-well tissue dishes (Costar, Cam-
bridge, USA), 5-20 x I04 in 3 ml of culture medium per
well. Cells growing as monolayer cultures were allowed to
attach for 24 h. Culture medium was removed and medium
containing TGF-3, was added (designated day 0). Loosely
adhering monolayer cultures were supplemented with TGF-
P3,-containing medium (day 0). Cells growing as floating ag-
gregates were seeded directly in TGF-p1-containing medium
(day 0). The cells were treated with TGF-P1 in concentrations
corresponding to absence of ligand (OpM), the average KD
for TGF-PI binding to the TGF-,B receptors (20 pM) (Dam-
strup et al., 1993), saturation of the receptors (100 pM) and
excess of ligand (250 pM). Fresh medium containing TGF-P,
was added every 48 h. Growth data were based on repeated
(approximately 48 h) harvest and assaying of triplicate wells
of each of the four TGF-PI concentrations. Samples of cells
growing strictly as monolayer cultures (CPH 54A and CPH
54B) were assayed for total protein (see below). All other
cells were assayed for DNA content (see below). Each experi-
ment was extended until the plateau phase of the growth
curve for the control (TGF-P, 0 pM) was reached. All
experiments were reproduced at least twice.
Protein determination
Culture medium was removed from the six-well dishes and
the cells were washed twice with cold phosphate-buffered
saline (PBS). The cells were solubilised in solubilisation
buffer [128 mM sodium chloride, 0.25 mM EDTA, 0.5 mM
Tris pH 7.5 and 1% (v/v) Triton X-100]. Protein concentra-
tion was determined using the BCA protein kit (Pierce
Europe, Oud Beijerland, The Netherlands) (Smith et al.,
1985).
DNA determination
Medium containing cells was sampled and the plates were
further harvested by trypsinisation. The cells from each well
were pelleted by centrifugation (1,200g, 10min) and
homogenised by ultrasonication in 1.0-2.0 ml of fluorimetry
buffer (2.0 M sodium chloride, 10 mM Tris, 5 mM EDTA,
pH 7.4). The DNA content of 20 LIl of homogenate plus
2.0 ml of fluorimetry buffer containing 0.1 tgml-' bisben-
zimide (Hoechst dye no. 33258) was determined by fluori-
metry (Labarca & Paigen, 1980) with an excitation wave-
length of 365 nm and an emission wavelength of 460 nm
(Hoefer fluorimeter TKO 100).
Immunocytochemistry
Exponentially growing cells were harvested by trypsinisation
and seeded on eight-well slide glasses (Flow). After 2 days
the cells were fixed with 4% paraformaldehyde-PBS
(10 min), washed with PBS (5 min), permeabilised with
methanol (1 min) and rewashed with PBS (15 min). The cells
were blocked with 0.1% BSA-PBS, and incubated with
monoclonal anti-pRb antibody, PMG3-245 (PharMingen, La
Jolla, CA, USA) (40 min, 37°C) in concentrations of 0, 5 and
10figml-'. The cells were washed with 0.1% BSA-PBS
(5min x 3) and incubated with FITC-coupled rabbit anti-
mouse immunoglobulin antibody (Dakopatts, Glostrup, Den-
mark), 1:30 in blocking buffer [25 mM Tris, 125 mM sodium
chloride 0.1% (v/v) Tween-20, 4% BSA, 10 mM sodium
azide], with 0.01 mg ml-' Evans blue (30min, 37°C). Finally
the cells were washed with PBS (5min x 3). Examination
and photography were performed with a Leitz Aristoplan
microscope equipped with appropriate filters.
Statistics
The total content of protein or DNA was expressed relative
to the content at day 0 to obtain a relative increment in cell
number. Growth curves were constructed by plotting the
relative increment as a function of time. Each growth curve
was parameterised using quadratic regression on the log-
transformed increments. The estimated coefficients of treated
and control cells were compared using multivariant statistics
and the significance level expressed. as a P-value. Values
below 0.01 were regarded as significant.
Results
Growth suppression
The results of the TGF-P, treatment and the immuno-
cytochemical investigation of pRb localisation are sum-
marised in Table I together with previous characteristics of
the examined cell lines. TGF-1, treatment resulted in growth
suppression exclusively in the cell lines expressing TGF-p-r
type II: CPH 54A and CPH 54B expressing all three types of
receptors, GLC 16 and GLC 19 expressing receptor types I
and II and DMS 273 expressing receptor types II and III.
The growth of the two cell lines expressing only type III
receptor, DMS 114 and GLC 3, and the two TGF-p-r-804 P. N0RGAARD et al.
Table I TGF-P receptor expression, pRb expression and phosphorylation level,
nuclear localization of pRb and in vitro growth suppression by TGF-P1 in nine
SCLC cells
TGF-P receptor' Phosphorylation Nuclear TGF-f, growth
Cell line I II III pRbb levelb pRb suppression
CPH 54A + + + + p + +
CPH 54B + + + + p + +
GLC 16 + + - - c c +
GLC 19 + + - - c c +
DMS 273 - + + + NP - +
DMS 114 - - + + P + -
GLC 3 - - + NT c c
DMS 53 - - - + P + -
GLC 14 - - c c
aData on TGF-P receptor expression from Damstrup et al. (1993). bData on
pRb expression and phosphorylation level from Rygaard et al. (1990). cNot
tested because of lack of pRb expression. -, negative; +, TGF-P receptor,
expression ofpRb, nuclear localisation ofpRb detected, or growth suppressed by
TGF-,1; P, phosphorylated pRb; NP, underphosphorylated pRb; NT, not tested.
negative cell lines DMS 53 and GLC 14, was unaffected by
TGF-P, treatment. The P-values for comparisons between the
individual growth curves obtained after treatment with the
four different concentrations ofTGF-P1 are given in Table II.
These results demonstrate the significance (P-value below
0.01) of the above-mentioned TGF-P1 growth suppression.
The results also show that growth suppression was dose
dependent within the applied range ofTGF-13I concentrations
in the cell lines GLC 16, GLC 19 and DMS 273. The growth
curves of DMS 273 are shown in Figure 1. It appears that
half-maximal growth suppression was obtained with 20pM
TGF-,1, and maximal growth suppression with 100 pM,
whereas excess of ligand (250 pM) did not result in further
growth suppression. The significant difference between the
control and 250 pM growth curves for the receptor-negative
cell line DMS 53 (Table II) reflects an apparent growth
inhibition by TGF-pl, occurring very late in the experiment,
i.e. after 200 h.
Morphological changes
The two SCLC cell lines CPH 54A and CPH 54B expressed
all three receptor types (Table I), and normally have a
monolayer growth morphology. In these cell lines, the TGF-
PI-induced growth suppression was accompanied by changes
in morphology, assessed by light microscopy. The cells began
to aggregate, pile up and detach. The changes were not dose
dependent within the applied range of TGF-PI concentra-
tions. Figure 2 illustrates the changes in CPH 54A. These
changes are representative of what was seen in both CPH
54A and CPH 54B. In none of the other cell lines examined
did TGF-P1 induce apparent morphological changes.
Nuclear localisation ofpRb
The five cell lines previously reported to express pRb (Table
I) were examined by immunocytochemistry. In four of the
cell lines, CPH 54A, CPH 54B, DMS 114 and DMS 53,
intense nuclear staining indicating nuclear localisation of
pRb was seen in the majority of cells and a weak nuclear
staining was seen in a small number of cells. In contrast,
DMS 273 lacked nuclear staining, and preparations of this
cell line without Evans blue cytoplasmic counterstaining
showed a weak nuclear staining (data not shown). This
indicated expression of a non-functional pRb. The pRb in
DMS 273 also lacked the ability to become phosphorylated
(Table I). Figure 3 shows representative fields of the slides of
CPH 54A, DMS 114 and DMS 273.
Discussion
In a previous study we reported that different combinations
of the three TGF-p-r types were expressed by a panel of 21
SCLC cell lines (Damstrup et al., 1993). These findings
enabled us to investigate a possible functional diversity of the
receptor types, and in the present study we examined the
effect of TGF-P1 on the growth of seven TGF-p-r-expressing
and two TGF-p-r-negative SCLC cell lines. TGF-P1 induced
growth suppression in two cell lines expressing all three
receptor types, two cell lines expressing types I and II recep-
tors and one cell line expressing receptor types II and III.
The growth of two cell lines expressing only the type III
receptor and the two receptor-negative cell lines were not
suppressed by TGF-P, (Table I). These results showed that
Table II Estimated P-values for comparisons of growth curves obtained after in vitro treatment
of nine SCLC cell lines with different concentrations of TGF-P, (0, 20, 100 and 250pM). Values
below 0.01 are considered significant
Cell line 0/20pM 0/100pM 0/250pM 20/100pM 20/250pM 100/250pM
CPH 54A 0.00 0.00 0.00 0.04 0.13 0.71
CPH 54B 0.00 0.00 0.00 0.02 0.00 0.03
GLC 16 0.00 0.00 0.00 0.79 0.00 0.00
GLC 19 0.55 0.00 0.00 0.00 0.01 0.13
DMS 273 0.00 0.00 0.00 0.00 0.00 0.58
DMS 114 0.91 0.56 0.15 0.44 0.12 0.44
GLC 3 0.93 0.83 1.00 0.98 0.95 0.84
DMS 53 0.09 0.14 0.00 0.98 0.03 0.01
GLC 14 0.62 0.70 0.45 0.92 0.89 0.90
0/20pM, 0/100PM and 0/250pM, comparison of growth curves for control cells (OpM) and
treated cells (20, 100 and 250pM respectively). 20/100 pM, 20/250pM and 100/250 pM,
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/ -A Figure 2 TGF-p,-induced morphological changes in the SCLC
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Figure 1 Growth curves for the SCLC cell line DMS 273,
obtained after in vitro treatment with the following TGF-P, con-
centrations: a, 20pm; b, 100pM; c, 250pm. The relative incre-
ment in cell number was plotted as a function of time. Values are
mean of triplets ± s.d. 0, untreated cells; A, treated with TGF-
Pt.
only in the cell lines expressing TGF-p-r type II did treat-
ment with TGF-01 result in growth suppression, and this
suggested that in SCLC TGF-p-r type II mediated the
growth-suppressive effect of TGF-p,. The maximum growth
inhibition was approximately the same in all the responding
cell lines, and as expected the inhibitory effect emerged later
in the slower growing cell lines. This indicated that in SCLC
no obligatory coexpression between TGF-p-rII and type I or
III was required for mediation of TGF-P1 growth suppres-
sion. However, this panel of cell lines did not include cells
expressing TGF-p-rII or TGF-p-rI alone, or TGF-p-rI co-
expressed with TGF-p-rIII. Therefore, it could not be estab-
lished whether these receptor profiles were capable of
mediating a response to TGF-p1. An apparent growth inhibi-
tion of the TGF-P-r-negative cell line DMS 53 did occur very
late in the experiment with high TGF-P, concentrations. A
possible explanation could be that this cell line expressed
TGF-p-r in a concentration below the detection limit with
chemical cross-linking and radioreceptor assays.
A few reports have elucidated the issue of functional div-
ersity and/or correlation among the TGF-P receptors, and it
has become apparent that different mechanisms operate in
different model systems. In a recent study, Geiser et al.
(1992) used a human bladder carcinoma and a human colon
adenocarcinoma, which were both resistant to the growth-
inhibitory action of TGF-, but responded to TGF-P by
producing increased levels of mRNA for extracellular matrix
proteins. When fused, a non-tumorigenic hybrid was pro-
duced, in which the effect of TGF-f on growth was restored,
accompanied by a marked increase in TGF-p-rII expression.
In another report, transfection of hepatoma cells with the
type II receptor cDNA resulted in restoration of growth
suppression by TGF-P, (Inagaki et al., 1993). Our present
results support these findings, and emphasise the role of
TGF-p-r type II in mediating growth inhibition, because the
SCLC cell line DMS 273 represents the first reported case of
growth suppression by TGF-P1 mediated by the type II recep-
tor without coexpression of the type I receptor (Table I and
Figure 1).
A model for functional interrelation between TGF-p-rI and
-II was recently presented (Wrana et al., 1992), based on
studies of mutated mink lung epithelial cells (Boyd & Mas-
sague, 1989; Laiho et al., 1990a,b, 1991; Wrana et al., 1992).
According to this model TGF-p-rI and TGF-p-rII form a
heterodimeric complex for signalling of the various effects of
TGF-P, including suppression of growth. As described above,
our present results concerning the SCLC cell line DMS 273
do not agree with this heteromeric TGF-P receptor model.
However, the possibility exists that DMS 273 expressed
TGF-P-rI at a concentration below the detection limit of the
chemical cross-linking assay (Damstrup et al., 1993).
TGF-P is supposed to be a central regulator in the normal
coordination of growth and differentiation, through auto-
crine and paracrine mechanisms. A perturbation of the
balance between negative and positive growth regulators
could lead to an increased proliferative potential, and con-
tribute to the neoplastic phenotype (Moses et al., 1988). We
previously reported coexpression of TGF-P and TGF-p-r in
six of 21 examined SCLC cell lines (Damstrup et al., 1993).
One of the cell lines whose growth was in this study supp-
ressed by TGF-P, to the'same degree as the others (GLC 16)
did not express TGF-P mRNA of any subtype. Two of the
coexpressing cell lines expressed only the type III receptor
(DMS 114 and GLC 3) and their growth was not suppressed
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Figure 3 Immunocytochemical detection of Rb protein in SCLC
cell lines, using a monoclonal anti-pRb antibody, and cytoplas-
mic counterstaining with Evans blue. a, CPH 54B; b, DMS 114;
c, DMS 273. These fields of view are representative of what was
seen in the whole slides. Magnification x 800.
by TGF-pJ. It is possible that in these three cell lines,
together with the cell lines that expressed TGF-P mRNA but
no receptors (Damstrup et al., 1993), loss of autocrine
growth inhibition by TGF-P contributes to the malignant
phenotype. It can, however, be concluded from the present
result that this putative mechanism in tumour progression is
not a general phenomenon in SCLC.
Induction of altered morphology by TGF-1 was previously
described (Fanger et al., 1986; Koyasu et al., 1988; Boyd &
Kaufman, 1990), and could be expected from its effect on the
expression of a wide variety of structural proteins (reviewed
in Massague, 1990). The morphological changes reported
varied among different cell types. Two of the cell lines in this
study (CPH 54A and CPH 54B) responded to treatment with
TGF-P, with morphological changes, in addition to growth
suppression. These cell lines, which normally grow as
monolayer cultures, began to aggregate, pile up and detach
in the presence of TGF-pl. The nature of these mor-
phological changes is not known but will be the subject of
further investigation. In one experiment we removed TGF-,B,-
containing medium from CPH 54B and added fresh medium
to evaluate if the morphological and growth-suppressive re-
sponses were reversible. The cells regained the growth rate of
the control cells. An increase in number of cells with normal
growth morphology was seen, whereas the number of ag-
gregates persisted (data not shown). The morphological re-
sponse to TGF-P, could not be correlated to any pattern of
receptor expression, though none of the other cell lines re-
sponded with altered morphology as evaluated with light
microscopy. CPH 54A and CPH 54B were the only cell lines
in this study which expressed all three receptor types (Table
I), but given the knowledge that TGF-1-rIII apparently has
no direct role in signal transduction, and the finding that the
growth suppression was equal in all responsive cell lines, it
seemed unlikely that the coexpression of TGF-p-rIII in CPH
54A and CPH 54B, alone should determine this
difference.
We also examined the possible involvement of the retino-
blastoma protein in mediating the growth inhibition of TGF-
P1. Previously the expression of Rb mRNA and pRb in our
panel of SCLC cell lines was characterised (Rygaard et al.,
1990). Western blotting showed expression of pRb in five of
the nine cell lines examined in this study (Table I), but in
DMS 273 the protein was not phosphorylated. Given the fact
that pRb was isolated from exponentially growing cells, and
thus representative of all cell cycle phases, the dephos-
phorylation of the protein in DMS 273 indicated that it was
non-functional (Templeton et al., 1991). Using immunocyto-
chemistry, we further investigated the functional state ofpRb
by evaluating the amount of nuclear localisation of the pro-
tein (Table I). Only CPH 54A, CPH 54B, DMS 114 and
DMS 53 showed predominantly nuclear staining (Figure 3).
Aberrant, non-functional, protein products of mutated Rb
genes have been characterised and shown to have lost the
ability to become hyperphosphorylated and to associate with
nuclear structures (Szekely et al., 1991; Templeton et al.,
1991). Our present results showed that an SCLC cell line
expressing non-functional pRb (DMS 273) or cell lines
wihout pRb expression (GLC 16 and GLC 19) can be growth
inhibited by TGF-p,. These findings indicated that in these
cell lines there was no correlation between responsiveness to
the growth-suppressive effect of TGF-P, and expression of
functional pRb, and strongly suggest that in SCLC pRb is
not an obligatory component in the TGF-P, growth suppres-
sion pathway. This conclusion is in agreement with the
finding that TGF-P could inhibit the growth of mammary
carcinoma cell lines in the complete absence of pRb expres-
sion (Ong et al., 1991). In contrast, evidence has been pro-
vided that pRb plays a part in the TGF-P signalling pathway
in mink lung epithelial cells (Laiho et al., 1990b) and in
human skin keratinocytes (Pietenpol et al., 1990). It was
found that TGF-P, inhibition of proliferation involves sup-
pression of c-myc expression and is abrogated by pRb-bind-
ing viral transforming proteins (Pietenpol et al., 1990). The
c-myc promoter region mediating this effect, called the TGF-
P control element, is also required for pRb suppression of
c-myc (Pietenpol et al., 1991). The role of pRb in the TGF-P
signalling pathway is apparently not definitive, and TGF-P
signal transduction therefore probably functions through
different mechanisms in different cell types.
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